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Clinical Research Article
Background: Rapid and complete reversal of neuromuscular blockade (NMB) is desirable at the end of surgery. Sugam-
madex reverses rocuronium-induced NMB by encapsulation. It is well tolerated in Caucasian patients, providing rapid 
reversal of moderate (reappearance of T2) rocuronium-induced NMB. We investigated the efficacy and safety of sugam-
madex versus neostigmine in Korean patients.
Methods: This randomized, safety assessor-blinded trial (NCT01050543) included Korean patients undergoing general 
anesthesia. Rocuronium 0.6 mg/kg was given prior to intubation with maintenance doses of 0.1-0.2 mg/kg as required. 
Patients received sugammadex 2.0 mg/kg or neostigmine 50 μg/kg with glycopyrrolate 10 μg/kg to reverse the NMB at 
the reappearance of T2, after the last rocuronium dose. The primary efficacy endpoint was the time from sugammadex or 
neostigmine administration to recovery of the train-of-four (TOF) ratio to 0.9. The safety of these medications was also 
assessed.
Results: Of 128 randomized patients, 118 had evaluable data (n = 59 in each group). The geometric mean (95% confi-
dence interval) time to recovery of the TOF ratio to 0.9 was 1.8 (1.6, 2.0) minutes in the sugammadex group and 14.8 
(12.4, 17.6) minutes in the neostigmine group (P < 0.0001). Sugammadex was generally well tolerated, with no evidence 
of residual or recurrence of NMB; four patients in the neostigmine group reported adverse events possibly indicative of 
inadequate NMB reversal.
Conclusions: Sugammadex was well tolerated and provided rapid reversal of moderate rocuronium-induced NMB in 
Korean patients, with a recovery time 8.1 times faster than neostigmine. These results are consistent with those reported 
for Caucasian patients. (Korean J Anesthesiol 2013; 65: 501-507)
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Introduction 
Neuromuscular blockade (NMB) is widely used during sur-
gery to facilitate tracheal intubation and to minimize patient 
movement during the surgical procedure. After surgery, rapid 
reversal of the NMB is desirable to improve patient comfort and 
safety [1], and to prevent post-operative complications such as 
hypoxia, weakness, and respiratory failure, which may increase 
patient morbidity [2,3]. 
Neostigmine, an acetylcholinesterase inhibitor, is commonly 
used in clinical practice in Korea to reverse NMB [4]. Adverse 
effects associated with acetylcholinesterase inhibitors include 
bradycardia, bronchoconstriction, and increased gastric motility 
[5]. Anticholinergic agents are usually administered in combina-
tion with acetylcholinesterase inhibitors to reduce these effects, 
but these agents are also associated with adverse effects such as 
blurred vision and tachycardia [6]. 
Sugammadex, a selective relaxant-binding agent, rapidly and 
completely reverses the effects of the neuromuscular blocking 
agents rocuronium and vecuronium [1,7,8]. It was approved 
in the European Union in 2008 for the reversal of moderate 
(reappearance of the second twitch of the train-of-four [TOF] 
response [T2]; sugammadex 2.0 mg/kg) and deep (1-2 post-
tetanic counts; sugammadex 4.0 mg/kg) NMB induced by 
rocuronium or vecuronium, and is currently approved in more 
than 70 countries worldwide. The present study investigated the 
use of sugammadex for reversing moderate NMB.
In Caucasian patients, sugammadex at 2.0 mg/kg has been 
demonstrated to provide significantly faster reversal of moderate 
NMB than neostigmine [7]. In this pivotal study for this indica-
tion, the geometric mean time to recovery of the TOF ratio to 0.9 
was 1.5 minutes with sugammadex compared to 18.6 minutes 
with neostigmine after each agent was administered at the reap-
pearance of T2 [7]. To date, sugammadex has not been studied 
in Korean patients. 
This was a local registration trial in Korea to evaluate and 
compare the efficacy and safety of sugammadex 2.0 mg/kg with 
neostigmine 50 μg/kg for reversal of moderate rocuronium-
induced NMB in Korean patients. Moderate, rather than deep, 
NMB was chosen based on guidelines from the Korea Food and 
Drug Administration. A secondary objective of the study was to 
demonstrate similar recovery times as those observed in Cauca-
sian patients based on data from a pivotal Phase III clinical trial 
of similar design conducted in Europe [7].
Materials and Methods
This randomized, parallel-group, active-controlled, safety as-
sessor-blinded phase IV study (NCT01050543; sponsor protocol 
number P06101) was conducted at seven sites in the Republic 
of Korea. The study was conducted in accordance with the prin-
ciples of Good Clinical Practice and was approved by the appro-
priate Institutional Review Boards and regulatory agencies. All 
patients provided written informed consent before enrollment.
Adult patients were eligible for inclusion in the study pro-
vided they were American Society of Anesthesiologists Class 1, 2, 
or 3, scheduled for an elective surgical procedure under general 
anesthesia using rocuronium for tracheal intubation and main-
tenance of NMB, and required reversal of NMB. All patients 
were to be of Korean descent, born in Korea, never having emi-
grated out of Korea, and with a Korean home address. Exclusion 
criteria were any anatomical malformation that might cause 
difficult intubation; any patient transferred to the intensive care 
unit after surgery; neuromuscular disorders that could affect the 
NMB; significant renal or hepatic dysfunction; requirement of 
a pneumatic tourniquet during surgery; (family) history of ma-
lignant hyperthermia; allergy to opioids/opiates, cyclodextrins 
including sugammadex, muscle relaxants and their excipients, or 
other medications used during general anesthesia; administra-
tion of toremifene and/or fusidic acid within 24 hours of study 
drug administration (or plan to administer these drugs within 
24 hours after study drug administration); any condition contra-
indicating neostigmine and/or glycopyrrolate; pregnant females; 
participation in a previous sugammadex study; participation in 
another clinical drug study within 30 days inclusive of signing 
consent for the current study; or a member of, or related to, the 
investigational staff or sponsor staff.
Eligible patients were randomized on a 1 : 1 basis to receive 
either sugammadex 2.0 mg/kg or neostigmine 50 μg/kg plus gly-
copyrrolate 10 μg/kg for NMB reversal. Anesthesia was induced 
with intravenous propofol and maintained with inhalational 
sevoflurane. Opioids were administered according to local prac-
tice when clinically required. Neuromuscular monitoring was 
carried out using continuous acceleromyography at the adductor 
pollicis muscle with the TOF-Watch SXⓇ (Organon Ireland Ltd., 
a subsidiary of Merck and Co., Swords, Co. Dublin, Ireland). 
Following induction of anesthesia, the TOF-Watch SXⓇ device 
was attached, stabilized, and calibrated. 
Rocuronium 0.6 mg/kg was administered as a single bolus 
dose for intubation, and NMB was maintained with one or more 
doses of 0.1 to 0.2 mg/kg rocuronium as clinically required. 
After the last dose of rocuronium, at the reappearance of T2, 
a single intravenous (IV) dose of sugammadex 2.0 mg/kg or a 
single IV dose of neostigmine 50 μg/kg plus glycopyrrolate 10 
μg/kg was administered to reverse the NMB.
Efficacy
The primary efficacy endpoint was the time from the start of 
administration of sugammadex or neostigmine to recovery of 
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the TOF ratio to 0.9. Secondary endpoints included time to re-
covery of the TOF ratio to 0.7 and 0.8. Time to reappearance of 
T2 after the last dose of rocuronium was also assessed.
Bridging analysis
A key secondary objective of the study was to show that the 
recovery time from moderate NMB with sugammadex in Ko-
rean patients was comparable to that observed in Caucasian pa-
tients from the rocuronium group of a similar study [7]. Specifi-
cally, we aimed to show that the geometric mean recovery time 
of the TOF ratio to 0.9 from administration of sugammadex 
was, with high confidence, less than 3 minutes.
Safety
Each patient was monitored for safety for up to 7 days after 
administration of the study drug. Safety variables comprised all 
reported adverse events (AEs, including serious AEs), coded us-
ing the Medical Dictionary for Regulatory Activities (MedDRA 
version 14.0), vital signs, physical examination, and clinical 
evidence of residual NMB and recurrence of NMB. A blinded 
safety assessor performed the safety assessments in the post-op-
erative period and in the follow-up period. The anesthesiologist 
administering the anesthesia during the surgical procedure was 
not blinded to the randomized study drug, but was not allowed 
to reveal the assigned treatment group to the safety assessor. 
Risk factors for post-operative nausea and vomiting (PONV) 
[9] were also assessed at baseline and used to assess the likeli-
hood that any occurrences of PONV were associated with the 
study therapy. Subsequent incidence of PONV was determined 
from AEs coded with the MedDRA-preferred terms of nausea, 
procedural nausea, vomiting, and procedural vomiting. 
Bridging analysis 
Safety results observed for Korean subjects in the current 
study were compared retrospectively with those observed for 
Caucasian subjects in the rocuronium group of a similar study [7].
Statistical analyses, populations, and sample size 
calculation
The primary efficacy endpoint was analyzed using a two-
way analysis of variance (ANOVA) model that included the 
treatment groups and study site factors. As recovery times were 
expected to follow a lognormal distribution [1], the response 
variable of the ANOVA model was the logarithm of the recovery 
time. A 95% confidence interval (CI) for the mean difference 
between the treatment groups was calculated on the log scale 
and transformed back onto the original scale, resulting in a CI 
for the ratio of the geometric mean recovery time after sugam-
madex dosing over the geometric mean recovery time after neo-
stigmine dosing. 
A hierarchical testing procedure was applied to cope with 
multiplicity due to performing two statistical tests related to the 
primary and secondary objectives of the study. First, the prima-
ry statistical comparison was performed at a significance level of 
5%. Only if that test was successful (i.e., a statistically significant 
faster recovery time to a TOF ratio of 0.9 with sugammadex 
compared to neostigmine) was the secondary objective (equiva-
lence with respect to time from sugammadex administration to 
recovery of the TOF ratio to 0.9 between Korean and Caucasian 
subjects) tested at a significance level of 5%. The hierarchi-
cal testing procedure followed the closed testing principle and 
maintained an overall error level of 5%. 
The all subjects treated (AST) group was used to report 
demographic and baseline characteristics and safety data, and 
included all randomized patients who received a dose of study 
medication. The primary efficacy analysis was performed on 
the intention-to-treat (ITT) group, which included all patients 
who received randomized treatment and had at least one effi-
cacy measurement. Data were imputed for patients with missing 
times to recovery of the TOF ratio to 0.7, 0.8, and 0.9 using a 
worst-case scenario for sugammadex and a best-case scenario 
for neostigmine. The per-protocol population comprised all sub-
jects from the ITT group without any major protocol violation.
Based on a previous study of similar design, in which geo-
metric mean times to recovery of the TOF ratio to 0.9 follow-
ing reversal of rocuronium were approximately 1.5 minutes 
for sugammadex and 18.6 minutes for neostigmine [7], and 
assuming that similar mean recovery times and variation would 
be observed in the Korean population in the present study, a 
sample size of 50 evaluable patients per treatment group was 
determined to provide sufficient power for the analyses. This 
would provide statistical confirmation of whether the geometric 
mean recovery time with sugammadex, with 95% confidence, 
is at least five times faster than the geometric mean time with 
neostigmine, and whether the geometric mean recovery time 
with sugammadex, with 95% confidence, is less than 3 minutes 
(i.e., not more than 1.5 minutes longer than the geometric mean 
recovery time of the Caucasian patients observed in the previ-
ous study [7]). All statistical analyses were performed using the 
software package SASⓇ (SAS Institute, Cary, NC, USA; version 
9.1 [Korean patients], version 8.2 [previous study in Caucasian 
patients]).
Safety data were analyzed using the AST population and 
summarized using descriptive statistics; no statistical tests were 
performed.
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Results
Overall, 128 patients were randomized in the study (Fig. 1). 
The AST population comprised 60 patients in each treatment 
group and the ITT population consisted of 59 patients in each 
group. Patient demographics were well balanced between the 
two treatment groups (Table 1). The types of elective surgical 
procedures performed were generally comparable between the 
two groups, with the most frequent procedures according to the 
Nordic Medico-Statistical Committee classification of surgical 
procedures being operations of the ear, nose, and larynx (48%), 
female genital organs (18%), and digestive system and spleen 
(17%).
The geometric mean time to recovery of the TOF ratio to 0.9 
was 1.8 minutes following administration of sugammadex 2.0 
mg/kg compared with 14.8 minutes following administration of 
neostigmine 50 μg/kg (Table 2). Based on statistical analysis of 
the logarithm of recovery times using a two-way ANOVA ad-
justed for trial site, recovery was estimated to be 8.1 times faster 
with sugammadex than with neostigmine (95% CI 6.8-9.6 times 
faster; P < 0.0001). Data were imputed for 3 patients in the su-
gammadex group and 11 patients in the neostigmine group. An 
analysis using only data from patients who had results available 
provided similar outcomes: for those patients with complete 
data (sugammadex, n = 56; neostigmine, n = 48), the geometric 
mean time to recovery of the TOF ratio to 0.9 was 1.7 minutes 
following administration of sugammadex 2.0 mg/kg compared 
with 15.3 minutes following administration of neostigmine 50 
μg/kg. 
Similar differences between the treatment groups were ob-
served for recovery of the TOF ratio to 0.7 and 0.8: recovery 
times following sugammadex administration were 5.6 and 7.5 
times faster, respectively, versus neostigmine (P < 0.0001 for 
both). 
For each of the time-to-recovery endpoints (recovery of the 
TOF ratio to 0.7, 0.8, and 0.9), a statistically significant main ef-
fect of the trial site effect was observed (P < 0.0001), indicating 
that the geometric mean times, adjusted for treatment group, 
were not comparable across the seven trial sites. However, there 
was no statistically significant interaction between the trial site 
and treatment group for the time-to-recovery endpoints in the 
Fig. 1. Patient disposition.
Table 1. Summary of Patient Baseline Characteristics (All-subjects-treated 
Population)
Sugammadex
(n = 60)
Neostigmine
(n = 60)
Sex, n (%)
    Male 
    Female 
Race, n (%)
    Asian
Age, yr
Weight, kg
Height, cm
ASA class, n (%)
    Class 1
    Class 2
39 (65)
21 (35)
60 (100)
41.3 (14.0)
66.6 (10.6)
167.5 (7.9)
51 (85)
9 (15)
37 (62)
23 (38)
60 (100)
42.6 (14.0)
65.1 (10.3)
166.5 (8.3)
48 (80)
12 (20)
Data are given as means (SD) unless otherwise specified. ASA: American 
Society of Anesthesiologists.
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sensitivity analysis, indicating that the treatment effect of su-
gammadex versus neostigmine was homogenous across the trial 
sites. 
Fig. 2 illustrates the cumulative percentage of patients for the 
time taken to recover to a TOF ratio of 0.9, based on the per-
protocol populations with complete recovery data available. 
For most patients (89.3%; 50/56 patients) in the sugammadex 
group, the time to recovery of the TOF ratio to 0.9 was less than 
3 minutes (Fig. 2). By comparison, in the neostigmine group, it 
took 38.5 minutes before a similar proportion of patients (89.4%; 
42/47 patients) had recovered to a TOF ratio of 0.9 and no pa-
tients recovered within 3 minutes. The geometric mean times to 
recovery of T2 after the start of administration of the last dose 
of rocuronium were similar in both groups: 26.2 minutes in the 
sugammadex group and 29.0 minutes in the neostigmine group. 
The geometric mean times to recovery of the TOF ratio to 0.9 
for Korean and Caucasian patients following administration of 
sugammadex 2.0 mg/kg at the return of T2 were comparable be-
tween the two patient groups (1.8 and 1.5 minutes, respectively; 
Table 2). In both patient populations, the upper limit of the 
geometric mean 95% CI was less than the pre-specified criterion 
of 3 minutes (the upper 95% CIs were 2.0 and 1.7 minutes for 
Korean and Caucasian patients, respectively).
The percentage of patients who experienced an AE was simi-
lar between the groups, with a total of 98 AEs reported in 41 
(68%) patients who received sugammadex, and a total of 117 
AEs reported in 44 (73%) patients who received neostigmine 
(Table 3). Most AEs were of mild or moderate intensity. The 
percentage of subjects reported to have experienced at least one 
non-serious AE of severe intensity was similar between the treat-
ment groups. In the sugammadex group, two subjects (3%) expe-
rienced a severe headache, while in the neostigmine group three 
subjects (5%) experienced severe AEs: one subject experienced a 
severe headache and two subjects experienced severe incision site 
pain. Treatment-related AEs (i.e., those that were considered to 
be possibly or probably related to the study drug) were reported 
for four (7%) patients in the sugammadex treatment group, and 
six (10%) patients in the neostigmine treatment group. In the 
sugammadex group, these were cardiac anesthetic complication 
(bradycardia of moderate intensity, n = 1) and headache (n = 3); 
in the neostigmine group, they were headache (n = 2), nausea, 
recurrence of NMB, rash, and hypotension (n = 1). 
Serious AEs were reported for two patients in each treatment 
group, all of which were considered unlikely to be related to the 
study drug. In the sugammadex group, these included a severe 
intestinal anastomosis in a 69-year-old male and a severe post-
operative abscess in a 48-year-old female. In the neostigmine 
group, these were metastases to the bone (severe) in a 56-year-
old male with maxillary sinus squamous cell carcinoma, and 
moderate dysuria in a 45-year-old female.
PONV was reported in three patients in the sugammadex 
group and six patients in the neostigmine group (Table 4). All 
patients from both treatment groups who experienced PONV 
had at least two baseline PONV risk factors.
There were no clinically relevant differences between the 
treatment groups in mean systolic or diastolic blood pressures 
or heart rate. 
Table 2. Time (Minutes) from Administration of Sugammadex/neostigmine to Recovery of the Train-of-four (TOF) Ratio to 0.7, 0.8, and 0.9, 
Including a Comparison with the Recovery Times Observed in Caucasian Patients following Sugammadex Administration (Intention-to-treat 
Population, with Imputed Data for Missing Values)
Sugammadex
(n = 59)
Neostigmine
(n = 59)
Sugammadex [Caucasian patients]†
(n = 46)
Time to TOF ratio 0.7
Time to TOF ratio 0.8
Time to TOF ratio 0.9
Geometric mean (95% CI)
Range
Geometric mean (95% CI)
Range
Geometric mean (95% CI)
Range
1.2 (1.1-1.3)
0.6-3.0
1.4 (1.2-1.5)
0.7-4.1
1.8 (1.6-2.0)
1.0-8.3
7.1 (6.0-8.4)*
2.8-33.4
10.7 (9.0-12.6)*
3.3-42.3
  14.8 (12.4-17.6)*
4.1-80.6
1.1 (1.0-1.2)
0.7-2.7
1.3 (1.2-1.4)
0.9-3.4
1.5 (1.3-1.7)
0.9-5.4
*P < 0.0001 for sugammadex versus neostigmine (Korean patients). †Results from the Caucasian patients, who participated in a previous similar 
study [7], are shown for bridging purposes. CI: confidence interval. 
Fig. 2. Patients (%) reaching a train-of-four (TOF) ratio of 0.9 after 
administration of sugammadex or neostigmine (per-protocol population, 
with data available). 
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No AEs that would be potentially indicative of inadequate 
reversal of NMB were reported for any sugammadex patients. 
In the neostigmine group, four patients (7%) reported AEs that 
were possibly indicative of inadequate reversal (mild amblyopia, 
mild asthenia and two cases of mild recurrence of NMB). 
The most frequently occurring AEs (occurring in ≥ 10% of 
Korean or Caucasian patients who received sugammadex) are 
listed in Table 5. A lower proportion of treatment-emergent AEs 
were reported for Korean patients (68% in the sugammadex 
group) than for Caucasian patients (85% in the sugammadex 
group) (Table 5). Headache was reported more frequently in 
Korean patients than for Caucasian patients (12% and 4%, 
respectively), while nausea and vomiting were reported more 
frequently in Caucasian patients (24% and 17% vs. 7% and 3%, 
respectively, in Korean patients). 
Discussion 
To date, sugammadex has been extensively studied in West-
ern patients living in Europe and the USA for the reversal of 
moderate and deep NMB [1,7,8], but it is important to investi-
gate it in other patient populations, particularly because ethnic-
ity and geographic location may affect the potency and duration 
of action of many drugs [10-13].
This was the first randomized, active-controlled trial of suga-
mmadex in Korean patients, comparing recovery from rocuro-
nium-induced NMB between sugammadex 2.0 mg/kg and 
neostigmine 50 μg/kg administered at the reappearance of T2 
(moderate blockade). In Korean patients, the recovery to a TOF 
ratio of 0.9 was approximately 8.1 times faster after administra-
tion of sugammadex compared with neostigmine, when admin-
istered at the reappearance of T2 (1.8 minutes compared with 
14.8 minutes, P < 0.0001). Geometric mean times to recovery 
of the TOF ratio to 0.9 in Korean patients were comparable to 
Table 4. Number of Apfel Post-operative Nausea and Vomiting (PONV) 
Risk Factors* at Baseline and Incidence of PONV Following Sugammadex 
and Neostigmine Administration (All-subjects-treated Population)
Number of 
risk factors at 
baseline*
Sugammadex (n = 60) Neostigmine (n = 60)
Patients  
with risk  
factors
Patients 
experiencing 
PONV
Patients  
with risk 
factors
Patients 
experiencing 
PONV
Zero
One
Two
Three
Four
  0
18
23
17
  2
0
0
2
1
0
  0
14
24
21
  1
0
0
2
4
0
*The Apfel risk factors for PONV are female gender, history of PONV or 
motion sickness, being a non-smoker, and post-operative administration 
of opioids [9]. 
Table 5. Summary of Treatment-emergent Adverse Events (AEs) Occurring 
in ≥ 10% of Korean and Caucasian Patients who Received Sugammadex in 
Either Study (All-subjects-treated Population)
AE  
(MedDRA-preferred term)
Percentage of patients
Korean patients 
(n = 60)
Caucasian patients†
(n = 46)
Patients with any AE
Procedural pain
Headache
Incision site pain 
Nausea
Vomiting
Pain
68%
33%
12%
12%
7%
3%
0%*
85%
41%
4%
0%*
24%
17%
22%
*Due to differences in the version of MedDRA used in the Korean and 
Caucasian studies (versions 14.0 and 9.0, respectively), these terms were 
not consistent between studies, resulting in 0% reported for the study 
whose MedDRA version did not contain that term. †Results from the 
Caucasian patients, who participated in a previous similar study [7], 
are shown for bridging purposes. MedDRA: Medical Dictionary for 
Regulatory Activities.
Table 3. Summary of Treatment-emergent Adverse Events (AEs) Occurring in ≥ 5% of Patients in Either Treatment Group (All-subjects-treated Population)
AE (MedDRA-preferred term)
Sugammadex Neostigmine
Number of patients (%)  
(n = 60) Overall number of events
Number of patients (%)  
(n = 60) Overall number of events
Any AE
Procedural pain
Incision site pain
Headache
Nausea
Wound complication
Rhinorrhea
Cough
Pyrexia
Procedural nausea
Dizziness
41 (68)
20 (33)
7 (12)
7 (12)
4 (7)
3 (5)
3 (5)
2 (3)
1 (2)
1 (2)
1 (2)
98
22
9
8
4
3
3 
2
1
1
1
44 (73)
18 (30)
12 (20)
  9 (15)
  4 (7)
  6 (10)
  0
  3 (5)
  3 (5)
  3 (5)
  3 (5)
117
19
16
10
4
6
0
3
3
3
3
MedDRA: Medical Dictionary for Regulatory Activities.
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those observed in a previous, similarly designed pivotal study in 
Caucasian patients (1.5 minutes and 18.6 minutes in the sugam-
madex and neostigmine groups, respectively) [7].
A key secondary objective of this study was to show that the 
geometric mean time to recovery of the TOF ratio following 
administration of sugammadex was, with 95% confidence, less 
than 3 minutes. The data confirmed this, with the upper limit of 
the 95% CI for geometric mean time to recovery at 2.0 minutes.
Treatment with sugammadex in Korean patients was gen-
erally well tolerated. A similar percentage of patients in each 
treatment group experienced at least 1 AE (68% in the sugam-
madex group and 73% in the neostigmine group). Serious AEs 
were reported for two patients in each group, while PONV was 
reported in three patients in the sugammadex group and six 
patients in the neostigmine group. Importantly, there was no 
evidence of residual or recurrence of NMB in patients who re-
ceived sugammadex in the present study, but there was evidence 
of inadequate NMB reversal (based on AE reporting) in 7% of 
patients who received neostigmine.
Compared to Caucasian patients from the previous study [7], 
a lower proportion of AEs was found in Korean patients (85% 
and 68%, for Caucasian and Korean patients, respectively). The 
overall safety profile was similar for both patient populations. 
In conclusion, sugammadex 2 mg/kg provided rapid and 
complete reversal of moderate rocuronium-induced NMB in 
Korean patients, and the time to recovery of the TOF ratio to 0.9 
was significantly (~8.1 times) faster with sugammadex than with 
neostigmine (P < 0.0001). The overall efficacy and safety profiles 
of sugammadex were similar to those previously observed for 
Caucasian patients in a comparable pivotal study that examined 
reversal of moderate NMB.
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